Publikationen in Zusammenarbeit mit Forschern von Instituto de Salud Carlos III (20)

2022

  1. Influx of kynurenine into the brain is involved in the reduction of ethanol consumption induced by Ro 61-8048 after chronic intermittent ethanol in mice

    British Journal of Pharmacology, Vol. 179, Núm. 14, pp. 3711-3726

2021

  1. 5-HT4Receptors Are Not Involved in the Effects of Fluoxetine in the Corticosterone Model of Depression

    ACS Chemical Neuroscience, Vol. 12, Núm. 11, pp. 2036-2044

  2. Addiction and the kynurenine pathway: A new dancing couple?

    Pharmacology and Therapeutics, Vol. 223

  3. Autoradiographic Visualization of G Protein-Coupled Receptors in Brain

    Neuromethods (Humana Press Inc.), pp. 161-174

  4. Decreased kynurenine pathway potentiate resilience to social defeat effect on cocaine reward

    Neuropharmacology, Vol. 197

  5. Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor

    Neuropharmacology, Vol. 187

2020

  1. Plasma tryptophan and kynurenine pathway metabolites in abstinent patients with alcohol use disorder and high prevalence of psychiatric comorbidity

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 102

  2. β-Catenin Role in the Vulnerability/Resilience to Stress-Related Disorders Is Associated to Changes in the Serotonergic System

    Molecular Neurobiology, Vol. 57, Núm. 3, pp. 1704-1715

2019

  1. Targeting β-Catenin in GLAST-Expressing Cells: Impact on Anxiety and Depression-Related Behavior and Hippocampal Proliferation

    Molecular Neurobiology, Vol. 56, Núm. 1, pp. 553-566

2018

  1. Increasing kynurenine brain levels reduces ethanol consumption in mice by inhibiting dopamine release in nucleus accumbens

    Neuropharmacology, Vol. 135, pp. 581-591

2017

  1. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus

    Neuropharmacology, Vol. 118, pp. 157-166

  2. Enhanced Stress Response in 5-HT1AR Overexpressing Mice: Altered HPA Function and Hippocampal Long-Term Potentiation

    ACS Chemical Neuroscience, Vol. 8, Núm. 11, pp. 2393-2401

2016

  1. The absence of 5-HT4 receptors modulates depression- and anxiety-like responses and influences the response of fluoxetine in olfactory bulbectomised mice: Adaptive changes in hippocampal neuroplasticity markers and 5-HT1A autoreceptor

    Neuropharmacology, Vol. 111, pp. 47-58

2014

  1. Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome

    Journal of Pineal Research, Vol. 56, Núm. 1, pp. 51-61

  2. Serotonin 5-HT4 receptors: A new strategy for developing fast acting antidepressants?

    Current Pharmaceutical Design, Vol. 20, Núm. 23, pp. 3751-3762

2013

  1. Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

    Journal of Neuroscience, Vol. 33, Núm. 9, pp. 3953-3966

  2. Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment

    Psychopharmacology, Vol. 229, Núm. 1, pp. 177-185

2011

  1. New strategies in the development of antidepressants: Towards the modulation of neuroplasticity pathways

    Current Pharmaceutical Design, Vol. 17, Núm. 5, pp. 521-533

2010

  1. Reduced signal transduction by 5-HT 4 receptors after long-term venlafaxine treatment in rats

    British Journal of Pharmacology, Vol. 161, Núm. 3, pp. 695-706

2009

  1. Long-term treatment with fluoxetine induces desensitization of 5-HT 4 receptor-dependent signalling and functionality in rat brain

    Journal of Neurochemistry, Vol. 110, Núm. 3, pp. 1120-1127